CDC Report: Drug-Resistant Germs Cause 50,800 US Deaths Annually

Key points

• The CDC's 2026 Antimicrobial Resistance Threats Report identifies 19 pathogens causing 9.7 million infections and 50,800 deaths yearly in the US.
• Four 'urgent threats' include Candida auris, carbapenem-resistant Acinetobacter, carbapenem-resistant Enterobacterales, and Neisseria gonorrhoeae.
• Candida auris cases increased nearly tenfold since 2019, with over 6,700 infections reported this year, primarily in healthcare settings.
• Carbapenem-resistant Enterobacterales (CRE) caused 14,878 infections and 1,252 deaths in 2023, with incidence rising 18% from 2019 to 2023.
• Clostridioides difficile (C. diff) was downgraded from an 'urgent' to a 'serious' threat after infection rates fell 21% between 2018 and 2020.
• Healthcare-associated drug-resistant infections cost over $12 billion and caused more than 42,000 deaths in 2023.

Background

The CDC previously released a similar report in 2019, which identified 2.8 million infections and 35,000 deaths. The current report reflects updated methodologies and data sources, making direct comparisons difficult, but highlights a significant rise in drug-resistant infections. The CDC categorizes threats into 'urgent,' 'serious,' and 'concerning' levels, with 'urgent' indicating the highest risk. Previous efforts to curb C. diff through infection control and antibiotic stewardship have shown measurable success, serving as a model for other pathogens.

How outlets are covering it

The Independent and USA Today emphasize the scale of the crisis, highlighting the 9.7 million infections and 50,800 deaths, and stress the need for public awareness and hygiene. ABC News focuses on the 'arms race' between bacteria and antibiotics, quoting experts on the difficulty of treating resistant strains and the importance of vaccination and handwashing. CIDRAP provides a more technical analysis, noting the 10-fold increase in C. auris cases since 2019 and the 18% rise in CRE incidence, while also highlighting the positive trend in C. diff reduction. All sources agree on the urgency of the situation but differ in emphasis: some focus on the economic and healthcare costs, while others highlight the clinical implications for patients and the need for new drug development. The CDC itself, through Director Erica Schwartz, stresses that the data is 'alarming' but also shows progress in some areas, urging continued action and better data collection.

Why it matters

Drug-resistant infections threaten the effectiveness of modern medicine, including surgeries, cancer treatments, and organ transplants. The rising number of infections and deaths underscores the need for better infection control, antibiotic stewardship, and new drug development. The economic burden of $12 billion in healthcare costs highlights the financial impact on the healthcare system. Public awareness and preventive measures, such as handwashing and vaccination, are crucial to slowing the spread of these pathogens. The report serves as a wake-up call for policymakers, healthcare providers, and the public to address this growing threat before it becomes even more unmanageable.

What to watch

The CDC will continue to monitor the 19 pathogens and update its threat list as new data emerges. Researchers and pharmaceutical companies are expected to accelerate the development of new antibiotics and antifungals to combat resistant strains. Healthcare facilities will likely implement stricter infection control measures, including enhanced screening and disinfection protocols, to prevent the spread of superbugs. Public health campaigns may focus on antibiotic stewardship and the importance of completing prescribed courses of medication. The CDC will also work to improve data collection and sharing to better track the spread of drug-resistant infections and guide policy decisions.